Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted ...

Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...